



PharmaMar to Host Research and Development Event on April 24, 2017

Madrid, April 6, 2017 – PharmaMar (MSE:PHM), a leading biopharmaceutical company focused on the discovery and development of innovative marine-derived anticancer drugs, today announced that it will host a Research and Development Event in New York on Monday, April 24th, 2017, from 10:30 am – 1:30 pm ET. The event will be hosted by members of PharmaMar’s senior management team and will feature presentations from expert speakers. Management and speakers will discuss scientific pipeline including; Phase 3 pivotal study with lurbinectedin (PM1183), current and prospective clinical trials, small-cell lung cancer and hereditary breast cancers, and an overview of Company strategy. Expert guest speakers to include:

- Melinda Telli, MD, Stanford University, Stanford School of Medicine, Stanford, CA
- Martin Forster, MBBS MRCP PhD, UCL Cancer Institute, University College Hospital, London, UK
- Sue Friedman, DVM, Executive Director of Facing Our Risks of Cancer Empowered (FORCE)

The presentation will be webcast simultaneously on the calendar section of the Company’s [Events Calendar](#) page of the website at www.pharmamar.com

A webcast replay will be available on the PharmaMar website for 30 days following the call by visiting the [Events Calendar](#) page of the company’s website at www.pharmamar.com.

About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain’s leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at www.pharmamar.com.

Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: + 34609493127
Paula Fernández – Media Relations Manager pfalarcon@pharmamar.com Mobile: +34 638796215
Phone: +34 918466000

**Investor Relations:**

José Luis Moreno Martínez-Losa – Head of Investor Relations and Capital Markets
investorrelations@pharmamar.com

Phone: +34 914444500

Or please visit our website at www.pharmamar.com

##